Expert exchange seminar on the clinical safety and effectiveness of recombinant human p53 adenovirus injection was held in Shenzhen
On December 15-16, 2018, an expert exchange seminar on the clinical safety and efficacy of "recombinant human p53 adenovirus injection" was held in Shenzhen. The attendees include over ten renowned p53 gene therapy experts and clinical research experts from both domestic and international sources.
This expert meeting discussed and summarized the clinical research and application of the past 20 years, and affirmed the safety, effectiveness, historical status, and clinical value of "recombinant human p53 adenovirus injection". It is of great significance for the future development of gene therapy in China and for the future development of Saibainuo. During the two-day expert meeting, each attending expert freely expressed their opinions and comprehensively expounded the safety and effectiveness of "recombinant human p53 adenovirus injection" in the clinical treatment of solid tumors from different clinical disciplines, combined with their own research and application experience. The attending experts unanimously believe that the clinical treatment of head and neck tumors caused by p53 functional mutations or deletions with "recombinant human p53 adenovirus injection" is safe and effective; At present, "recombinant human p53 adenovirus injection" is still the only existing gene therapy drug for tumor patients with p53 functional mutations or deletions, and it is irreplaceable.
Recombinant human p53 adenovirus injection "is developed and produced by Shenzhen Saibainuo Gene Technology Co., Ltd. It is the world's first marketed drug for gene therapy of cancer. Since its launch in 2004, over 30000 patients, including nearly 10% of international patients from over 50 countries, have received treatment with this product alone or in combination with radiotherapy, chemotherapy, hyperthermia, and other multiple therapies (internal data).
This meeting reviewed and summarized the clinical research and application of "recombinant human p53 adenovirus injection" in the past 20 years, and comprehensively evaluated the safety and effectiveness of "recombinant human p53 adenovirus injection".
